STERIS (NYSE:STE – Get Rating) was downgraded by investment analysts at TheStreet from a “b-” rating to a “c” rating in a research note issued to investors on Thursday, TheStreetRatingsTable reports.
A number of other equities research analysts also recently issued reports on the stock. Wolfe Research assumed coverage on shares of STERIS in a report on Tuesday, April 5th. They issued an “outperform” rating and a $275.00 price target on the stock. StockNews.com raised shares of STERIS from a “hold” rating to a “buy” rating in a report on Wednesday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $264.00.
Shares of STERIS stock opened at $192.78 on Thursday. STERIS has a 12-month low of $192.40 and a 12-month high of $255.93. The company has a market cap of $19.29 billion, a price-to-earnings ratio of 80.66 and a beta of 0.67. The company has a current ratio of 2.04, a quick ratio of 1.41 and a debt-to-equity ratio of 0.45. The company’s 50-day moving average price is $227.91 and its 200-day moving average price is $231.01.
In other STERIS news, VP John Adam Zangerle sold 8,000 shares of the stock in a transaction that occurred on Wednesday, April 20th. The shares were sold at an average price of $255.48, for a total transaction of $2,043,840.00. Following the transaction, the vice president now directly owns 31,023 shares in the company, valued at $7,925,756.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Karen L. Burton sold 4,000 shares of the stock in a transaction that occurred on Tuesday, March 29th. The shares were sold at an average price of $246.00, for a total transaction of $984,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,659 shares of company stock worth $5,573,759. 1.14% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the company. Tcwp LLC bought a new position in shares of STERIS in the first quarter worth approximately $25,000. 1832 Asset Management L.P. bought a new position in shares of STERIS in the first quarter worth approximately $25,000. Riverview Trust Co bought a new position in shares of STERIS in the first quarter worth approximately $29,000. J.W. Cole Advisors Inc. bought a new position in shares of STERIS in the first quarter worth approximately $37,000. Finally, Jackson Wealth Management LLC lifted its stake in STERIS by 3.0% in the third quarter. Jackson Wealth Management LLC now owns 14,282 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 420 shares during the period. Hedge funds and other institutional investors own 90.88% of the company’s stock.
About STERIS (Get Rating)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
- Get a free copy of the StockNews.com research report on STERIS (STE)
- Ride Out The Recession With These Dividend Kings
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.